Cancer Research

Ivan Kairatov is a seasoned Biopharma expert with a distinguished career in research and development, specializing in the technological innovations that drive drug discovery. His deep understanding of protein dynamics and structural biology makes him a leading voice in deciphering the complex

Ivan Kairatov is a seasoned biopharma expert whose career has been defined by a relentless pursuit of the molecular mechanisms that govern human health and disease. With an extensive background in research and development, Kairatov has spent years navigating the intricate pathways of tech-driven

The traditional decade-long timeline for oncology drug development is finally collapsing under the weight of generative models that predict protein folding with near-perfect accuracy. For years, the pharmaceutical industry struggled with high failure rates in clinical trials, often seeing promising

The rapid evolution of therapeutic interventions in the oncology sector has necessitated a fundamental shift in how clinical success is quantified, moving beyond immediate tumor shrinkage toward a comprehensive evaluation of patient outcomes over several years. Historically, the primary metrics for

Ivan Kairatov joins us to discuss the shifting landscape of hematologic oncology, bringing his deep expertise in biopharmaceutical innovation to the forefront of the conversation. As a researcher who has spent years navigating the complex pathways of drug development, Kairatov offers a unique

The traditional methodology of identifying genetic mutations in cancer patients often relies on time-consuming processes that destroy precious biopsy samples before a treatment plan can even begin. This fundamental conflict between diagnostic necessity and sample preservation has led to the